Psoriasis: A clinical update on diagnosis and new therapies

Cleveland Clinic Journal of Medicine

Volumn 67, Issue 2, 2000, Pages 105-119

  Camisa, Charles ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CALCIPOTRIOL; CALCITRIOL; COAL TAR; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; ETRETIN; HYDROXYUREA; KERATOLYTIC AGENT; LACTIC ACID; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PSORALEN; RETINOID; RETINOL; SALAZOSULFAPYRIDINE; SALICYLIC ACID; TACROLIMUS; TAZAROTENE; TIOGUANINE; UREA; VITAMIN D DERIVATIVE;

ARTHRITIS; CLINICAL FEATURE; CLINICAL PROTOCOL; DISEASE SEVERITY; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PHOTOTHERAPY; PSORIASIS; REVIEW; SKIN TOXICITY; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

EID: 0033968025     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.67.2.105     Document Type: Review

References (37)

1. Kirsner RS, Federman DG. Managed care: The dermatologist as a primary care provider. J Am Acad Dermatol 1995; 33:535-537.
2. Bohm M, Voorhees J, and the Committee on Psoriasis. White paper on hospitalization for psoriasis care. J Am Acad Dermatol 1984; 10:842-851.
3. Stern RS. Utilization of outpatient care for psoriasis. J Am Acad Dermatol 1996; 35:543-545.
4. Camisa C. Handbook of Psoriasis. Malden, MA: Blackwell Science, 1998.
5. Nanda A, Kaur S, Kaur I, Kumar B. Childhood psoriasis: an epidemiologic survey of 112 patients. Pediatr Dermatol 1990; 7:19-21.
6. Henderson CA, Highet AS. Acute psoriasis associated with Lancefield group C and group G cutaneous streptococcal infections. Br J Dermatol 1988; 118:559-562.
7. Leung DY, Traverse JB, Giorno R, et al. Evidence for a streptococcal super antigen-driven process in acute guttate psoriasis. J Clin Invest 1985; 96:2106-2112.
8. Ryan TJ, Baker H. The prognosis of generalized pustulopsoriasis. Br J Dermatol 1971; 85:407-411.
9. Ohkawara A, Yasuva H, Kobayashi H, et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences and symptoms and genetic background. Acta Derm Venereol 1996; 76:68-71.
10. Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 1989; 21:985-991.
11. McFadyen T, Lyell A. Successful treatment of generalized pustular psoriasis (von Zumbusch) by systemic antibiotics controlled by a blood culture. Br J Dermatol 1971; 85:274-276.
12. Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: outcome of disease subsets in relationship of joint disease to nail and skin disease. Br J Rheumatol 1994; 33:834-839.
13. Rosen K, Mobaken H, Swanbeck B. PUVA, etretinate, and PUVA-etretinate therapy for pustulosis palmoplantaris. Arch Dermatol 1987; 123:885-889.
14. Ellis CN, Voorhees JJ. Etretinate therapy. J Am Acad Dermatol 1987; 16:267-291.
15. Goldfarb MJ, Ellis CN, Gupta AK, et al. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol 1988; 18:655-662.
16. Maier H, Honigsmann H. Concentration of etretinate in plasma and subcutaneous fat in 10 female patients with longterm acitretin treatment [abstract]. Br J Dermatol 1996; 135:837.
17. Ashley JM, Lowe NJ, Ellis CN. Retinoids and alterations in lipid metabolism. In: Roenigk HH Jr, Maibach HI, eds. Psoriasis. 2nd ed. New York: Marcel Dekker, 1991:749-755.
18. Weinstein GG. Safety, efficacy, and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. Br J Dermatol 1996; 135 Suppl 49:32-36.
19. Roenigk HH Jr, Bergfeld WF, Curtis GH. Methotrexate for psoriasis in weekly oral doses. Arch Dermatol 1969; 99:86-93.
20. Hassan W. Methotrexate and liver toxicity: role of surveillance liver biopsy: conflict between guidelines for rheumatologists and dermatologists. Ann Rheum Dis 1996; 55:273-275.
21. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19:145-156.
22. Roenigk HH Jr, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38:478-485.
23. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during Methotrexate therapy for rheumatoid arthritis. A double-blind placebo-controlled trial. Ann Intern Med 1994; 121:833-841.
24. Beien NK, Bjerke JR, Rossmann-Ringdahl I, Jackson HB. Once-daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol 1997; 137:581-586.
25. Perez A, Raab R, Chen TC, et al. Safety and efficacy of oral calcitriol (1, 25-dihydroxy vitamin D3) for the treatment of psoriasis. Br J Dermatol 1996; 134:1070-1078.
26. Prystowski JH, Knobler EH, Muzio PJ. Oral calcitriol does not augment UVB phototherapy for plaque psoriasis. J Am Acad Dermatol 1996; 35:272-274.
27. Layton AM, Sheehan-Dare RA, Goodfield MJD, Cotterill JA. Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol 1989; 121:647-653.
28. Duvivier A, Munro DD, Berbov J. Treatment of psoriasis with azathioprine. Br Med J 1974; 1:49-51.
29. Silvis NG, Levine N. Pulse dosing of thioguanine in recalcitrant psoriasis. Arch Dermatol 1999; 135:433-437.
30. Zackheim HS, Glogau RG, Fisher DA, Maibach HI. 6-Tnioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol 1994; 30:452-458.
31. Kitchin JES, Pomeranz K, Pak G, et al. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and its potential uses. J Am Acad Dermatol 1997; 37:445-449.
32. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis, a review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987; 17:962-971.
33. Gupta AK, Ellis CN, Siegel MT, et al. Sulfasalazine improves psoriasis. A double-blind analysis. Arch Dermatol 1990; 126:487-493.
34. Gupta AK, Grower JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: A double-blind, placebo-controlled trial. J Rheumatol 1995; 22:894-898.
35. Combe B, Gouipille P, Kuntz JL, et al. Sulfasalazine in psoriatic arthritis: a randomized, multi-centre, placebo-controlled study. Br J Rheumatol 1996; 35:664-668.
36. European FK 506 Multi-centre Psoriasis Study Group. Systemic tacrolimus (FK-506) is effective for the treatment for psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 1996; 132:419-423.
37. Zonneveld IM, Rubins A, Jablonska S, et al. Topical tacrolimus is not effective in chronic plaque psoriasis: a pilot study. Arch Dermatol 1998; 134:1101-1102.